Insider buying last 90 days
No open-market insider purchases were filed for CLBT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CLBT insider filing, plotted on the chart in Gekko.Open CLBT in Gekko
NASDAQ: CLBT
Cellebrite DI (CLBT) Stock Analysis & Forecast
Oct 12 close
$11.44+0.18 (+1.6%)
Gekko Brief
AI summaryOct 12 closeCellebrite remains under pressure following its guidance cut and the CEO transition disclosed after the Q2 2026 report, when annual recurring revenue and revenue came in below management expectations amid delayed large deals tied to new procurement and administrative requirements around cloud and AI adoption. That August report triggered a sharp share price reaction, and the aftermath has drawn securities investigations from Kaplan Fox and Pomerantz on behalf of investors, alongside continued commentary weighing the risk of the guidance miss against the stock's valuation. Seven analysts covering the stock maintain Buy ratings with a consensus target of $15.36.
The stock closed at $11.44, up 1.6%, but remains below both its 50-day average of $12.06 and 200-day average of $13.86, with the shorter average also under the longer one, reflecting a continued downtrend; the one-year return stands at -39.9%. The GekkoIndex reads 59.7, placing it in the Neutral zone. Price sits 15% below Gekko Fair Value of $13.46.
The next earnings date falls on 11 November 2026, 29 days out and beyond a typical 20-trading-day hold; the prior report saw a -27% reaction against an average absolute move of 13.8%. No insider, Congress, or unusual options activity appears in the current windows. Seasonality over the past 5 years shows an average 20-day return of 0.8%, positive in 3 of those years.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Cellebrite DI price vs fair value
Close $11.44200-day averageGekko Fair Value $13.46
Cellebrite DI quick facts
- Market cap
- $2.85B
- P/E ratio
- 49.4
- Forward P/E
- 35.7
- EPS, TTM
- $0.23
- Revenue, TTM
- $514.3M
- Profit margin
- 11.4%
- Dividend yield
- —
- Beta
- 1.13
- Volume
- 1.60M avg 2.47M
- 1-year return
- −39.9%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±8.7%
- 50-day average
- $12.06
- 200-day average
- $13.86
- Next earnings
- Nov 11 before open
- Shares outstanding
- 251.3M
Cellebrite DI swing-trade checklist
Cellebrite DI scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $11.44 is below the 50-day ($12.06) and 200-day ($13.86) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
59.7, Neutral
Reading 59.7 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
15.0% below
Price is 15% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.8% on average
From this point in the calendar, the next 20 trading days averaged +0.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cellebrite DI stock chart and price history
Cellebrite DI closed at $11.44 on Oct 12, 2026, −39.9% over the past year, inside a 52-week range of $9.58 to $19.98.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.9%
- 3 months
- −29.3%
- 6 months
- −3.1%
- 1 year
- −39.9%
The full CLBT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CLBT in Gekko
Follow Cellebrite DI through every session
Put CLBT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CLBT in GekkoFree for 7 days. No credit card required.
About Cellebrite DI
Cellebrite DI makes software used by investigators who are legally authorized to examine digital evidence. Its platform lets users pull data from devices, review it, make sense of what they find, and track a case from the first search through to the final report. Investigators rely on these tools for matters like child exploitation, homicide, terrorism, border enforcement, sexual assault, trafficking, corporate security breaches, IP theft, and civil lawsuits. The company is most associated with its Universal Forensic Extraction Device, a tool meant to unlock phones, break through encryption, recover erased files, and surface hidden material that would otherwise stay out of reach.
Its product line also includes Seeker, which reviews video recordings, OSINT Analyze, which searches open sources across the surface web, deep web, and dark web in real time, and Crypto Tracer, which traces blockchain activity and pulls in outside data to flag and sort digital wallets. Buyers of these tools include government offices at the federal, state, and local level, along with businesses and firms that provide related services.
Cellebrite DI traces back to 1999 and runs its main office out of Petah Tikva, Israel, while maintaining a presence in places like the United States, Germany, Singapore, Australia, Brazil, the United Kingdom, France, Canada, Japan, and India. The stock trades on the NASDAQ under the ticker CLBT.
- Listed
- NASDAQ
- Sector
- Technology services
- Industry
- Packaged software
- Website
- cellebrite.com
Cellebrite DI GekkoIndex: the smart money zone
Cellebrite DI’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, down 2.2 points over five sessions.
59.7Neutral
Down 2.2 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 41 | +1.8% | 0.0% |
| Accumulation | 196 | +1.5% | +2.3% |
| Neutral (current zone) | 388 | −0.2% | +1.0% |
| Distribution | 44 | −0.4% | +1.2% |
| Selling | 13 | +5.8% | +14.3% |
Average CLBT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CLBT price, zone by zone.Track CLBT in Gekko
Is Cellebrite DI stock overvalued? Gekko Fair Value
Cellebrite DI trades 15.0% below Gekko Fair Value of $13.46, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cellebrite DI shares are worth, recalculated every trading day.
$13.46
Gekko Fair Value, Oct 9, 2026
15.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CLBT in Gekko
Cellebrite DI insider and Congress trading
No open-market insider purchases were filed for Cellebrite DI, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CLBT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CLBT, plotted on the chart in Gekko.Open CLBT in Gekko
Buybacks
Cellebrite DI has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $11K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold CLBT.
2added0opened2trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Cellebrite DI earnings: next date and track record
Cellebrite DI reports on Nov 11, 2026, before the open (30 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected before the open, 30 days away
- EPS estimate
- $0.17
- Revenue estimate
- $145.9M
5 of 8reports beat the EPS estimate
±13.8%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Cellebrite's Q2 2026 earnings call covered an executive transition (Shiv Ramji named CEO), an acknowledgment that ARR and revenue underperformed management expectations for the quarter, and explanations centered on timing of several large deals that slipped due to new procurement and administrative requirements tied to cloud/AI adoption and foreign entity status. Management highlighted ARR growth of 21% to $508M, strong geographic growth (notably APAC at 29%), product momentum (Advanced Unlocks, Guardian Investigate, and the newly launched Genesis with ~$400k ARR late in June), and improving gross revenue retention. They characterized 2026 as an "execution reset" while reiterating long-term confidence in cloud and AI-driven platform opportunities. Management took accountability for the shortfall, described steps taken to address procurement and permit issues (including securing a master FEP), and emphasized that the company is being more prudent in outlook and deal handicapping going forward.
- Risks flagged
- Procurement and administrative delays (e.g., freedom of information requirements in EMEA, foreign entity permit/FEP requirements in U.S. federal procurements), elongated sales cycles for large cloud/AI platform deals (approx. ~6-week elongation reported), potential lower pricing/expansion on Insights migrations versus prior periods, and regulatory/sovereignty concerns around cloud data handling that could add friction.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | $0.05 est $0.09 | $131.1M est $131.5M | −27.0% |
| May 14, 2026 | $0.12 est $0.09 | $128.3M est $127.0M | +7.3% |
| Feb 11, 2026 | $0.09 est $0.14 | $128.8M est $126.1M | −8.3% |
| Nov 12, 2025 | $0.14 est $0.09 | $126.0M est $123.0M | +22.8% |
| Aug 14, 2025 | $0.12 est $0.10 | $113.3M est $112.2M | +11.5% |
| May 14, 2025 | $0.10 est $0.05 | $107.5M est $109.3M | −14.2% |
| Feb 13, 2025 | $0.10 est $0.10 | $109.0M est $109.4M | −17.7% |
| Nov 6, 2024 | $0.14 est $0.09 | $106.9M est $107.2M | −1.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cellebrite DI stock forecast and analyst price targets
Analysts’ average 12-month price target for Cellebrite DI is $15.36, +34.3% from the last close, from 7 firms rating the stock in the last 90 days.
$15.36consensus 12-month target, +34.3% from the last close
Now $11.44Avg $15.36
Low $12.50High $16
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | D.A. Davidson | $15 | +31.1% |
| Aug 14 | Lake Street | $15 | +31.1% |
| Aug 14 | Deutsche Bank | $14 | +22.4% |
| Aug 14 | J.P. Morgan | $16 | +39.9% |
| Aug 14 | Needham | $12.50 | +9.3% |
+1.0%average 20-day move after past Neutral readings
+0.8%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cellebrite DI seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Cellebrite DI averaged +0.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.0% | 3 of 5 |
| Next 10 trading days | +3.5% | 2 of 5 |
| Next 15 trading days | +2.2% | 3 of 5 |
| Next 20 trading days | +0.8% | 3 of 5 |
| Next 30 trading days | +0.6% | 3 of 5 |
For scale, CLBT’s typical 20-trading-day move in either direction is about 8.7%.
Cellebrite DI market cap and key statistics
Cellebrite DI’s market cap is $2.85B, with a P/E ratio of 49.4 and revenue of $514.3M over the last twelve months.
Valuation
- Market cap
- $2.85B
- P/E ratio
- 49.4
- Forward P/E
- 35.7
- EPS, TTM
- $0.23
- Gekko Fair Value
- $13.46
Trading
- Volume
- 1.60M
- Avg volume, 20 days
- 2.47M
- 52-week high
- $19.98
- 52-week low
- $9.58
- Shares outstanding
- 251.3M
Financials
- Revenue, TTM
- $514.3M
- Profit margin
- 11.4%
- Return on equity
- 12.4%
- Quarterly earnings growth, YoY
- −67.9%
Risk and income
- Beta
- 1.13
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±8.7%
Cellebrite DI stock news this week
Coverage of Cellebrite DI this week reads negative: 1 positive, 5 neutral and 5 negative headlines.
- Cellebrite DI (CLBT) Following CEO Change And Guidance Cut Looks Caught Between Risk And ValueSimply Wall Street, Oct 11
- What Investors Got Wrong About Cellebrite DI Before The DropSimply Wall Street, Oct 10
- Pertento Partners Reports 5.2% Ownership Stake in Cellebrite DI Ltd.Kalkine Media, Oct 10
- Advisory clients hold the shares behind a reported passive stake above 5% in Cellebrite (CLBT).Stock Titan, Oct 9
- Kaplan Fox Announces an Investigation of Cellebrite DI Ltd. (NASDAQ: CLBT) on Behalf of Long-Term InvestorsThe Globe and Mail, Oct 9
- Cellebrite CFO plans USD 267,160 sale. Analysts target Cellebrite stock at USD 15.36AD HOC NEWS, Oct 8
Cellebrite DI peers
Cellebrite DI’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 21.7% above |
| PLTRPalantir Technologies | Distribution | 22.3% above |
| ORCLOracle | Neutral | 24.3% below |
| PANWPalo Alto Networks | Neutral | 21.6% above |
| CRWDCrowdStrike | Neutral | 23.7% above |
| CRMSalesforce | Neutral | 3.6% below |
A peer links to its own page where one exists.
Cellebrite DI stock FAQ
What is Cellebrite DI’s market cap?
Cellebrite DI’s market cap is $2.85B at the Oct 12, 2026 close of $11.44, with 251.3M shares outstanding. The shares trade on a P/E ratio of 49.4.
What is the Cellebrite DI stock forecast?
The consensus analyst 12-month price target for Cellebrite DI is $15.36, +34.3% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cellebrite DI stock overvalued or undervalued?
On Gekko’s estimate Cellebrite DI is undervalued: the Oct 12, 2026 close of $11.44 is 15.0% below Gekko Fair Value of $13.46. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Cellebrite DI report earnings next?
Cellebrite DI is expected to report on Nov 11, 2026, before the market opens (30 days away). Analysts expect earnings of $0.17 per share on revenue of $145.9M. Cellebrite DI beat the earnings estimate in 5 of its last 8 reports, moving 13.8% on average across the report.
What is Cellebrite DI’s 52-week high and low?
Cellebrite DI’s 52-week high is $19.98 and its 52-week low is $9.58; it closed at $11.44 on Oct 12, 2026, −39.9% over the past year. Over the last five years the shares peaked at $26.30 on Feb 6, 2025.
Is Cellebrite DI stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cellebrite DI the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.